Preferred Label : gadopiclenol;
MeSH Hyperonym : 3,6,9,15-Tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetic acid,
alpha, alpha', alpha''-tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-, gadolinium
salt (1:1);
UNII : S276568KOY;
Origin ID : C000656634;
UMLS CUI : C5392287;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
- Gadolinium 2,2',2''-(3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triyl)tris(5-((2,3-dihydroxypropyl)amino)-5-oxopentanoate) [MeSH concept]
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.ema.europa.eu/en/medicines/human/EPAR/vueway
2024
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
gadopiclenol
contrast media
gadopiclenol
drug approval
europe
gadopiclenol
magnetic resonance imaging
adult
child
product surveillance, postmarketing
central nervous system
liver
kidney
pancreas
lung
prostate
breast
musculoskeletal system
Gadolinium Enhancement
injections, intravenous
pregnancy
breast feeding
---
https://www.has-sante.fr/jcms/p_3554609/fr/vueway-gadopiclenol-diagnostic
2024
false
false
false
France
insurance, health, reimbursement
contrast media
gadopiclenol
adult
child
magnetic resonance imaging
blood-brain barrier
central nervous system
central nervous system
liver
liver
kidney
kidney
pancreas
pancreas
breast
breast
lung
lung
prostate
prostate
musculoskeletal system
musculoskeletal system
evaluation of the transparency committee
gadopiclenol
---
https://www.has-sante.fr/jcms/p_3554605/fr/elucirem-gadopiclenol-diagnostic
2024
false
false
false
France
gadopiclenol
contrast media
insurance, health, reimbursement
adult
child
magnetic resonance imaging
cerebrum
cerebrum
liver
liver
kidney
kidney
pancreas
pancreas
lung
lung
prostate
prostate
breast
breast
blood-brain barrier
musculoskeletal system
musculoskeletal system
evaluation of the transparency committee
gadopiclenol
---
https://www.ema.europa.eu/en/medicines/human/EPAR/elucirem
2024
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
contrast media
gadopiclenol
gadopiclenol
drug approval
europe
adult
child
adolescent
magnetic resonance imaging
risk management
product surveillance, postmarketing
blood-brain barrier
liver
kidney
pancreas
lung
prostate
breast
musculoskeletal system
---